The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthma
Abstract
Summary: Background Patients with severe asthma are often inadequately controlled on existing anti‐asthma therapy, constituting an unmet clinical need. Objective This randomized, double‐blind, placebo‐controlled trial evaluated the ability of omalizumab, a humanized monoclonal anti‐IgE antibody, to improve disease control sufficiently to enable inhaled corticosteroid reduction in patients with severe allergic asthma. Methods After a run‐in period when an optimized fluticasone dose (1000 μg/day) was received for 4 weeks, patients were randomized to receive subcutaneous omalizumab [minimum 0.016 mg/kg/IgE (IU/mL) per 4 weeks; n=126] or matching placebo (n=120) at intervals of 2 or 4 weeks. The study comprised a 16‐week add‐on phase of treatment followed by a 16‐week fluticasone‐reduction phase. Short‐/long‐acting β 2‐agonists were allowed as needed. Results Median reductions in fluticasone dose were significantly greater with omalizumab than placebo: 60% vs. 50% (P=0.003). Some 73.8% and 50.8% of patients, respectively, achieved a 50% dose reduction (P=0.001). Fluticasone dose reduction to 500 μg/day occurred in 60.3% of omalizumab recipients vs. 45.8% of placebo‐treated patients (P=0.026). Through both phases, omalizumab reduced rescue medication requirements, improved asthma symptoms and asthma‐related quality of life compared to placebo. Conclusion Omalizumab treatment improves asthma control in severely allergic asthmatics, reducing inhaled corticosteroid requirements without worsening of symptom control or increase in rescue medication use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Determining a minimal important change in a disease-specific quality of life questionnaire
JUNIPER, E. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90036-1 · Cited by 1,824
Busse, W., Corren, J., Lanier, B. Q., McAlary, M., Fowler-Taylor, A., Cioppa, G. D., van As, A., & Gupta, N. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.117880 · Cited by 1,307
Self-citationMeasuring Quality of Life in Asthma
Juniper, E. F., Guyatt, G. H., Ferrie, P. J., & Griffith, L. E. (1993) · American Review of Respiratory Disease · doi:10.1164/ajrccm/147.4.832 · Cited by 887
Solèr, M., Matz, J., Townley, R., Buhl, R., O'Brien, J., Fox, H., Thirlwell, J., Gupta, N., & Della Cioppa, G. (2001) · European Respiratory Journal · doi:10.1183/09031936.01.00092101 · Cited by 827
Self-citationFahy, J. V., Fleming, H. E., Wong, H. H., Liu, J. T., Su, J. Q., Reimann, J., Fick, R. B., & Boushey, H. A. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.155.6.9196082 · Cited by 713
Treatment of Allergic Asthma with Monoclonal Anti-IgE Antibody
Milgrom, H., Fick, R. B., Su, J. Q., Reimann, J. D., Bush, R. K., Watrous, M. L., & Metzger, W. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912233412603 · Cited by 704
SEARS, M. R., HERBISON, G. P., HOLDAWAY, M. D., HEWITT, C. J., FLANNERY, E. M., & SILVA, P. A. (1989) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.1989.tb02408.x · Cited by 599
The epidemic of allergy and asthma
Holgate, S. T. (1999) · Nature · doi:10.1038/35037000 · Cited by 586
Self-citationTreatment of Childhood Asthma With Anti-Immunoglobulin E Antibody (Omalizumab)
Milgrom, H., Berger, W., Nayak, A., Gupta, N., Pollard, S., McAlary, M., Taylor, A. F., & Rohane, P. (2001) · Pediatrics · doi:10.1542/peds.108.2.e36 · Cited by 525
Interpreting treatment effects in randomised trials
Guyatt, G. H., Juniper, E. F., Walter, S. D., Griffith, L. E., & Goldstein, R. S. (1998) · BMJ · doi:10.1136/bmj.316.7132.690 · Cited by 516
Humanization of an antibody directed against IgE.
Presta, L. G., Lahr, S. J., Shields, R. L., Porter, J. P., Gorman, C. M., Fendly, B. M., & Jardieu, P. M. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.5.2623 · Cited by 474
The role of allergy in the development of asthma
Holt, P. G., Macaubas, C., Stumbles, P. A., & Sly, P. D. (1999) · Nature · doi:10.1038/35037009 · Cited by 471
Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response.
Boulet, L. P., Chapman, K. R., Côté, J., Kalra, S., Bhagat, R., Swystun, V. A., Laviolette, M., Cleland, L. D., Deschesnes, F., Su, J. Q., et al. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.155.6.9196083 · Cited by 399
Costs of asthma according to the degree of severity
Serra-Batlles, J., Plaza, V, Morejon, E., Comella, A., & Brugues, J. (1998) · European Respiratory Journal · doi:10.1183/09031936.98.12061322 · Cited by 387
Casale, T. B. (2001) · JAMA · doi:10.1001/jama.286.23.2956 · Cited by 377
Ers Task Force on Difficult/therapy-Resistant Asthma, & Members of the Task Force: K.F. Chung and P. Godard (co-chairmen), E. A. (1999) · European Respiratory Journal · doi:10.1034/j.1399-3003.1999.13e43.x · Cited by 351
Rhinosinusitis in severe asthma
Bresciani, M., Paradis, L., Des Roches, A., Vernhet, H., Vachier, I., Godard, P., Bousquet, J., & Chanez, P. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.111593 · Cited by 345
Self-citationRecombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen–induced seasonal allergic rhinitis
Ädelroth, E., Rak, S., Haahtela, T., Aasand, G., Rosenhall, L., Zetterstrom, O., Byrne, A., Champain, K., Thirlwell, J., Cioppa, G. D., et al. (2000) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2000.108310 · Cited by 317
Self-citationTREATMENT OF ALLERGIC ASTHMA WITH MONOCLONAL ANTI-IgE ANTIBODY
Ilgrom, H. E. M., Ick, R. O. B. F., Ohn, J., Eimann, J. A. D. R., Ush, R. O. K. B., Arc, M., Atrous, L. W., Ames, W. J., & Roup, S. T. G. (1999) · Cited by 281
Inhibition of Allergic Reactions with Antibodies to IgE
Shields, R. L., Whether, W. R., Zioncheck, K., O’Connell, L., Fendly, B., Presta, L. G., Thomas, D., Saban, R., & Jardieu, P. (1995) · International Archives of Allergy and Immunology · doi:10.1159/000237010 · Cited by 183
Corne, J., Djukanovic, R., Thomas, L., Warner, J., Botta, L., Grandordy, B., Gygax, D., Heusser, C., Patalano, F., Richardson, W., et al. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119252 · Cited by 173
Self-citationLiu, J., Lester, P. M., Builder, S. E., & Shire, S. J. (1995) · Biochemistry · doi:10.1021/bi00033a020 · Cited by 147
Fox, J. A., Hotaling, T. E., Struble, C. B., Ruppel, J., Bates, D. J., & Schoenhoff, M. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21215-0 · Cited by 123
Cited by
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926
Self-citationGlobal strategy for asthma management and prevention: GINA executive summary
Bateman, E. D., Hurd, S. S., Barnes, P. J., Bousquet, J., Drazen, J. M., FitzGerald, M., Gibson, P., Ohta, K., O'Byrne, P., Pedersen, S. E., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00138707 · Cited by 3,203
Self-citationBritish Guideline on the Management of Asthma
British Thoracic Society Scottish Intercollegiate Guidelines Network (2008) · Thorax · doi:10.1136/thx.2008.097741 · Cited by 2,021
Reddel, H. K., Taylor, D. R., Bateman, E. D., Boulet, L.-P., Boushey, H. A., Busse, W. W., Casale, T. B., Chanez, P., Enright, P. L., Gibson, P. G., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200801-060st · Cited by 1,918
Self-citationHumbert, M., Beasley, R., Ayres, J., Slavin, R., Hébert, J., Bousquet, J., Beeh, K. ‐., Ramos, S., Canonica, G. W., Hedgecock, S., et al. (2005) · Allergy · doi:10.1111/j.1398-9995.2004.00772.x · Cited by 1,123
Self-citation
Metadata
- Authors
- Holgate, S. T., Chuchalin, A. G., Hébert, J., Lötvall, J., Persson, G. B., Chung, K. F., Bousquet, J., Kerstjens, H. A., Fox, H., Thirlwell, J., Cioppa, G. D., & on behalf of the Omalizumab 011 International Study Group
- Venue
- Clinical & Experimental Allergy
- Publisher
- Wiley
- Published
- 2004-04
- Volume
- 34
- Issue
- 4
- Pages
- 632-638
- ISSN
- 0954-7894 (ISSN-L)
- 1365-2222
- OpenAlex
- W2097981132
- Cited by
- 522
- References
- 23
- FWCI
- 20.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.